IRANO response assessment for brain metastases
Disappearance of all enhancing target and non-target lesions for ≥4 weeks; no new lesions; no steroids; clinically stable or improved
≥30% decrease in sum of longest diameters of target lesions for ≥4 weeks; no new lesions; stable or decreased steroid dose; clinically stable or improved
Does not qualify for complete response, partial response, or progressive disease
≥20% increase in the sum of longest diameters of target lesions; or unequivocal progression of enhancing non-target lesions; or new lesions; or substantial clinical decline
References
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group Lancet Oncol. 2015 Nov;16(15):e534-e542
doi:
10.1016/S1470-2045(15)00088-1
close